Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 9Terminated 3Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 14Thoracic 2Myeloid 2Breast 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Recurrence 1Hematologic Neoplasms 1Frailty 1

Interventions

Imatinib Mesylate 17Cytarabine 13Azacitidine 13Cyclophosphamide 11Decitabine 9Dasatinib 9Etoposide 8nilotinib 7Peripheral Blood Stem Cell Transplantation 7Busulfan 7Tacrolimus 6Polymerase Chain Reaction 6Idarubicin 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5Blood Specimen Collection 5ruxolitinib 4pegaspargase 4fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Methylprednisolone 4Hydroxyurea 4Filgrastim 4ponatinib 3Surveys and Questionnaires 3Rituximab 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Tretinoin × Myeloid × Clear all
NCT05175508 2022-01-03

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

The First Affiliated Hospital of Soochow University

Phase 2/3 Unknown
180 enrolled
MyeloidOther hematologic neoplasm

Frailty, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02717884 2018-10-18

TRANSATRA

University Hospital Freiburg

Phase 1/2 Unknown
60 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡